Renal insufficiency and magnesium deficiency correlate with a decreased formation of biologically active cholecalciferol: a retrospective observational study.


Journal

International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 19 07 2022
accepted: 03 09 2022
pubmed: 6 11 2022
medline: 25 2 2023
entrez: 5 11 2022
Statut: ppublish

Résumé

Vitamin D is synthesized in the skin or supplied. Cholecalciferol is hydroxylated in the liver to 25(OH) vitamin D [25D]. 25D is further hydroxylated in the kidney to 1,25(OH) vitamin D [1,25D]. Catabolism occurs by further hydroxylation. Magnesium is a cofactor of all involved hydroxylases. To investigate the association between renal function and serum magnesium levels, and the biologically active hormone 1,25D. Anonymised serum values of 25D, 1,25D, magnesium and creatinine measured in an outpatient cohort over 2 years were analysed. Renal function and magnesium level did not influence 25D values (r = - 0.144 and 0.030, respectively). Mean serum 1,25D values decreased from 106.5 ± 44.3 pmol/l in individuals with normal renal function to 51.7 ± 18.9 pmol/l in those with severe renal insufficiency (p < 0.01). A weak positive correlation was observed between 1,25D and eGFR (r = 0.317), and between 1,25D and serum magnesium (r = 0.217). Impaired renal function and low magnesium serum levels are slightly associated with low 1,25D concentrations. Measuring 25D, but not 1,25D, may overestimate the patient's vitamin D status. In patients with renal insufficiency adequate magnesium supply should be ensured.

Sections du résumé

BACKGROUND BACKGROUND
Vitamin D is synthesized in the skin or supplied. Cholecalciferol is hydroxylated in the liver to 25(OH) vitamin D [25D]. 25D is further hydroxylated in the kidney to 1,25(OH) vitamin D [1,25D]. Catabolism occurs by further hydroxylation. Magnesium is a cofactor of all involved hydroxylases.
AIM OBJECTIVE
To investigate the association between renal function and serum magnesium levels, and the biologically active hormone 1,25D.
METHOD METHODS
Anonymised serum values of 25D, 1,25D, magnesium and creatinine measured in an outpatient cohort over 2 years were analysed.
RESULTS RESULTS
Renal function and magnesium level did not influence 25D values (r = - 0.144 and 0.030, respectively). Mean serum 1,25D values decreased from 106.5 ± 44.3 pmol/l in individuals with normal renal function to 51.7 ± 18.9 pmol/l in those with severe renal insufficiency (p < 0.01). A weak positive correlation was observed between 1,25D and eGFR (r = 0.317), and between 1,25D and serum magnesium (r = 0.217).
CONCLUSION CONCLUSIONS
Impaired renal function and low magnesium serum levels are slightly associated with low 1,25D concentrations. Measuring 25D, but not 1,25D, may overestimate the patient's vitamin D status. In patients with renal insufficiency adequate magnesium supply should be ensured.

Identifiants

pubmed: 36334229
doi: 10.1007/s11096-022-01485-6
pii: 10.1007/s11096-022-01485-6
doi:

Substances chimiques

Cholecalciferol 1C6V77QF41
Magnesium I38ZP9992A
Vitamin D 1406-16-2
Vitamins 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-244

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Makris K, Bhattoa HP, Cavalier E, et al. Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein - A position paper from the IFCC committee on bone metabolism. Clin Chim Acta. 2021;517:171–97.
doi: 10.1016/j.cca.2021.03.002 pubmed: 33713690 pmcid: 8080555
Bosworth C, de Boer IH. Impaired vitamin D metabolism in CKD. Semin Nephrol. 2013;33:158–68.
doi: 10.1016/j.semnephrol.2012.12.016 pubmed: 23465502 pmcid: 3592201
Rosanoff A, Dai Q, Shapses SA. Essential nutrient interactions: does low or suboptimal magnesium status interact with vitamin D and/or calcium status? Adv Nutr. 2016;7:25–43.
doi: 10.3945/an.115.008631 pubmed: 26773013 pmcid: 4717874
Uwitonze AM, Razzaque MS. Role of magnesium in vitamin D activation and function. J Am Osteopath Assoc. 2018;118:181–9.
doi: 10.7556/jaoa.2018.037 pubmed: 29480918
Zittermann A. Magnesium deficit-overlooked cause of low vitamin D status? BMC Med. 2013;11:1–3.
doi: 10.1186/1741-7015-11-229
Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9(4):328. https://doi.org/10.3390/nu9040328 .
doi: 10.3390/nu9040328 pubmed: 28346348 pmcid: 5409667
Dusso A, Gonzalez EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2011;25:647–55.
doi: 10.1016/j.beem.2011.05.005 pubmed: 21872805
Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–35.
doi: 10.1359/JBMR.0301264 pubmed: 15040831
Reddy V, Sivakumar B. Magnesium-dependent vitamin-D-resistant rickets. Lancet. 1974;1:963–5.
doi: 10.1016/S0140-6736(74)91265-3 pubmed: 4133647
Lee FY, Islahudin F, Makmor-Bakry M, et al. Factors associated with the frequency of antihypertensive drug adjustments in chronic kidney disease patients: a multicentre, 2-year retrospective study. Int J Clin Pharm. 2021;43:1311–21.
doi: 10.1007/s11096-021-01252-z pubmed: 33677789 pmcid: 7936864
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
doi: 10.7326/0003-4819-150-9-200905050-00006 pubmed: 19414839 pmcid: 2763564
Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1763–8.
doi: 10.1213/ANE.0000000000002864 pubmed: 29481436
Vieth R. The pharmacology of vitamin D, including fortification strategies. Vitamin D. 2005;2:995–1015.
doi: 10.1016/B978-012252687-9/50064-4
Essig S, Merlo C, Reich O, et al. Potentially inappropriate testing for vitamin D deficiency: a cross-sectional study in Switzerland. BMC Health Serv Res. 2020;20:1097.
doi: 10.1186/s12913-020-05956-2 pubmed: 33246469 pmcid: 7694269
Quarenghi MC, Aubry E, Aeberhard C, et al. Vitamin D deficiency in the sunny corner of Switzerland. Praxis. 2017;106(24):1323–30. https://doi.org/10.1024/1661-8157/a002836 .
doi: 10.1024/1661-8157/a002836 pubmed: 29183217
Spatling L, Classen HG, Kulpmann WR, et al. Diagnosing magnesium deficiency current recommendations of the society for magnesium research. Fortschr Med Orig. 2000;118(2):49–53.
pubmed: 15700486
Costello RB, Nielsen F. Interpreting magnesium status to enhance clinical care: key indicators. Curr Opin Clin Nutr Metab Care. 2017;20:504–11.
doi: 10.1097/MCO.0000000000000410 pubmed: 28806179 pmcid: 5812344
Dai Q, Zhu X, Manson JE, et al. Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial. Am J Clin Nutr. 2018;108:1249–58.
doi: 10.1093/ajcn/nqy274 pubmed: 30541089 pmcid: 6693398
Reddy P, Edwards LR. Magnesium supplementation in vitamin D deficiency. Am J Ther. 2019;26:e124–32.
doi: 10.1097/MJT.0000000000000538 pubmed: 28471760

Auteurs

Jean-Pierre Rothen (JP)

Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056, Basel, Switzerland. jp.rothen@unibas.ch.

Jonas Rutishauser (J)

Clinical Trial Unit, Kantonsspital Baden, Faculty of Medicine, University of Basel, Basel, Switzerland.

Isabelle Arnet (I)

Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056, Basel, Switzerland.

Samuel S Allemann (SS)

Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH